Bangladesh Everest Pharmaceuticals Sotoraxibu Instructions

1. Common name Sotorasibu

Product name:Lumakras

Full names: Sotorasibu, Lumakras, AMG510, Sotorasibu

2. Indications

Sotoracib is indicated for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer(NSCLC).

Three. Dosage and usage

1.The recommended dose is 960mg once daily and continued until disease progression or unacceptable toxicity occurs.

2.Dose adjustment

(1)Dose reduction level of adverse reactions

First dose reduction:480mg once daily

Second dose reduction:240mg once daily

Intolerable240mg once daily:Stop

Missed dose: If you do not take a dose of sotoraxib within ≤6 hours, take the prescribed dose as soon as you remember the dose. If medication has not been taken for more than 6 hours, take the prescribed dose at the next scheduled time.

Overdose: Contact your doctor immediately.

Usage: Orally

4. Adverse reactions

Lymphocyte decrease(48%), Hemoglobin decrease(43%), Diarrhea(42%), ASTincrease(39%), Alanine aminotransferase elevation(28%), Musculoskeletal pain(35%), Decreased calcium(35%), Increased alkaline phosphatase(33%), Increased urinary protein(29%), Decreased sodium(28%), Nausea(26%), Fatigue(26%), Hepatotoxicity(2 5%), Albumin decrease(23%), Activated partial thromboplastin time(aPTT)Increase(23%), Cough(20%), Vomiting(17%), Constipation(16%) , dyspnea(16%), abdominal pain(15%), edema(15%), loss of appetite(13%), joint pain(12%), pneumonia(12%), rash(12%), etc.

Five. save

Store at room temperature, 20°C to25°C away from moisture and high temperatures, and keep sotoracib out of the reach of children.

Six. Mechanism of action

Sotoracib (AMG510)is an inhibitor ofKRASG12Ca tumor-limiting, mutated, oncogenic form ofKRAS RAS gt pase. Sotorasiibforms an irreversible covalent bond with KRAS’s unique cysteineG12C, locking the protein in an inactive state and preventing downstream signaling without affecting wild-type KRAS. SotorasiibblocksKRAS signaling, inhibits cell growth and promotes apoptosisKRAS G12C tumor cell line.

7. Things to note

1Hepatotoxicity

Sotorracibcan cause hepatotoxicity, which may lead to drug-induced liver injury and hepatitis. Monitor liver function tests every 3 weeks 3 months before starting sotorasiib treatment.(ALT, AST, and total bilirubin) and then monthly or as clinically indicated, and more frequently in patients with elevated transaminases or bilirubin. Depending on the severity of the adverse reaction, discontinue, reduce dose, or permanently discontinue sotoraxib.

2.Interstitial lung disease(ILD)/Pneumonia

Sotorasiib can cause fatalILD/pneumonia. Monitor patients for new or worsening symptoms of ILD/pneumonia (such as difficulty breathing, cough, fever). In patients with suspected ILD/pneumonia, discontinue sutoracib immediately or permanently if no other potential cause of ILD/pneumonia is identified.

3.Breastfeeding

Risk summary

There are no data on the presence of sotoraxib or its metabolites in breast milk, the effects on the breastfed infant, or milk production. Because of the potential for serious adverse reactions in breastfed children, advise women not to breastfeed during treatment with sotoraxib and for 1 weeks after the last dose.

4.Pediatric use

The safety and effectiveness of sotoracibhave not been established in pediatric patients.

The retail price of Everest Pharmaceuticals in Bangladesh is around 120mg56 tablets ranging from 4000 yuan to 5000 yuan. If you want to get more high-quality information, you can contact YaDE. YaDE will do its best to learn more about high-quality overseas drugs for you.

xa0

xa0